Evidence map›Paper›PMID 35608258›Full record

ArticleeLife2022

The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps.

Brendan Antiochos, Daniela Trejo-Zambrano, Paride Fenaroli, Avi Rosenberg, Alan Baer, Archit Garg, Jungsan Sohn, Jessica Li, Michelle Petri, Daniel W Goldman and 3 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Brendan AntiochosJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.ORCID 0000-0001-6166-9750
Daniela Trejo-ZambranoJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Paride FenaroliNephrology Unit, Parma University Hospital, Department of Medicine and Surgery, Parma, Italy.
Avi RosenbergJohns Hopkins University School of Medicine, Division of Pathology, Baltimore, United States.
Alan BaerJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Archit GargJohns Hopkins University School of Medicine, Department of Biophysics and Biophysical Chemistry, Baltimore, United States.
Jungsan SohnJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.ORCID 0000-0002-9570-2544
Jessica LiJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Michelle PetriJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Daniel W GoldmanJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Christopher MecoliJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Livia Casciola-RosenJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.ORCID 0000-0002-4172-1539
Antony RosenJohns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States.
Johns Hopkins University · US

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9M
Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
Mechanisms in Sjogrens SyndromeR01DE012354 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI ROSEN, ANTONY · 1998 to 2017
$3.4M
Mechanistic Studies of Cytoplasmic dsDNA-Sensing PathwaysR01GM129342 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI SOHN, JUNGSAN · 2018 to 2021
$1.6M
The Retroelement LINE1 and the DNA Sensor IF16 in Sjogren's SyndromeK08AR077100 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ANTIOCHOS, BRENDAN · 2021 to 2025
$794k
Optimizing the Approach to Identify Cancer-Associated MyositisK23AR075898 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MECOLI, CHRISTOPHER · 2019 to 2023
$773k
Zeiss LSM780 Confocal Microscope for a Core FacilityS10OD016374 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2013 to 2013
$584k
NIAMS NIH HHS K08 AR077100NIAMS NIH HHS K23 AR075898NIAMS NIH HHS P30 AR070254NIAMS NIH HHS R01 AR069572NIDCR NIH HHS R01 DE012354NIGMS NIH HHS R01 GM129342NIH HHS S10 OD016374
6 · The paper itself

Abstract

Background: Nucleic acid binding proteins are frequently targeted as autoantigens in systemic lupus erythematosus (SLE) and other interferon (IFN)-linked rheumatic diseases. The AIM-like receptors (ALRs) are IFN-inducible innate sensors that form supramolecular assemblies along double-stranded (ds)DNA of various origins. Here, we investigate the ALR absent in melanoma 2 (AIM2) as a novel autoantigen in SLE, with similar properties to the established ALR autoantigen interferon-inducible protein 16 (IFI16). We examined neutrophil extracellular traps (NETs) as DNA scaffolds on which these antigens might interact in a pro-immune context. Methods: AIM2 autoantibodies were measured by immunoprecipitation in SLE and control subjects. Neutrophil extracellular traps were induced in control neutrophils and combined with purified ALR proteins in immunofluorescence and DNase protection assays. SLE renal tissues were examined for ALR-containing NETs by confocal microscopy. Results: AIM2 autoantibodies were detected in 41/131 (31.3%) SLE patients and 2/49 (4.1%) controls. Our SLE cohort revealed a frequent co-occurrence of anti-AIM2, anti-IFI16, and anti-DNA antibodies, and higher clinical measures of disease activity in patients positive for antibodies against these ALRs. We found that both ALRs bind NETs in vitro and in SLE renal tissues. We demonstrate that ALR binding causes NETs to resist degradation by DNase I, suggesting a mechanism whereby extracellular ALR-NET interactions may promote sustained IFN signaling. Conclusions: Our work suggests that extracellular ALRs bind NETs, leading to DNase resistant nucleoprotein fibers that are targeted as autoantigens in SLE. Funding: These studies were funded by NIH R01 DE12354 (AR), P30 AR070254, R01 GM 129342 (JS), K23AR075898 (CM), K08AR077100 (BA), the Jerome L. Greene Foundation and the Rheumatology Research Foundation. Dr. Antiochos and Dr. Mecoli are Jerome L. Greene Scholars. The Hopkins Lupus Cohort is supported by NIH grant R01 AR069572. Confocal imaging performed at the Johns Hopkins Microscopy Facility was supported by NIH Grant S10 OD016374.

Indexed as

DNA-Binding ProteinsExtracellular TrapsLupus Erythematosus, SystemicMelanomaNuclear ProteinsPhosphoproteinsAutoantibodiesAutoantigensDeoxyribonucleasesHumansInterferonsNeutrophilsAIM2 protein, humanAutoantibodiesAutoantigensDeoxyribonucleasesDNA-Binding ProteinsIFI16 protein, humanInterferonsNuclear ProteinsPhosphoproteinsautoantibodiesautoimmunityhumanimmunologyinflammationmedicineneutrophil extracellular traps

Identifiers

PMID35608258
PMCPMC9129876
OpenAlexW4281398726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.